TIRZ GLP-2Check methods and identity
What the Japanese tirzepatide trial measured around the abdomen
1 numbered sourceSource years 2026
Peptides are short amino-acid chains linked by peptide bonds. Some act at receptors that respond to signals from the gut. Tirzepatide is a modified peptide that activates GIP and GLP-1 receptors. The “GLP-2” in this catalog label is an identifier and does not describe tirzepatide’s receptor targets. A 2026 analysis of SURMOUNT-J examined how abdominal fat measurements and metabolic markers changed in Japanese adults with obesity disease. [1]
The trial randomly assigned 225 adults without diabetes to tirzepatide or placebo with lifestyle support. The analysis examined measurements made before and after treatment. Investigators distinguished visceral fat, which sits deeper inside the abdomen around organs, from subcutaneous fat, which lies under the skin. They also examined liver fat, waist measurements and blood markers. Recording these separately allowed them to ask whether a change in total weight was accompanied by changes in particular fat depots. [1]
In the analysis, greater weight reduction was associated with greater reductions in visceral fat. Changes in waist measures were also strongly associated with changes in visceral fat. The investigators reported changes in several blood markers and in measurements after a glucose tolerance test. For example, they observed reductions in a marker of inflammation and changes in hormones associated with fat tissue. The trial provided the measurements needed to compare how the different outcomes moved together. [1]
The researchers randomized assignment to tirzepatide or placebo. They did not assign a particular reduction in visceral fat to each person. The correlations between measurements therefore cannot prove that a reduction in one fat depot caused all the changes in blood markers. They can help researchers investigate which measurements track closely enough to be informative in this population. [1]
The findings apply to adults enrolled under the study’s Japanese obesity-disease criteria. A waist measurement can be easy to collect, while direct fat measurements give more specific information about the tissue. The analysis helps explain what each contributed to understanding changes in the trial and why a scale alone cannot show where fat changed. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
- 1.Hironori Waki et al. Changes in Abdominal Adiposity and Associations with Metabolic Health Markers Following Tirzepatide in Japanese Participants with Obesity Disease: Results from the SURMOUNT-J Study. Endocrine Practice (publication 2026-09-19). (opens in a new tab)
pubmed.ncbi.nlm.nih.gov↩ Back to text
